Showing 3281-3290 of 6035 results for "".
- CooperVision Releases 4-Year Data on Landmark MiSight 1-Day Contact Lens Studyhttps://modernod.com/news/coopervision-releases-4-year-data-on-landmark-misight-1-day-contact-lens-study/2479874/New 4-year study data shows the the impact of a pioneering contact lens management approach to slowing the progression of myopia in children, including those whose treatment begins later, according to a CooperVision news release. CooperVision is presenting the multi-year study’s latest out
- LumiThera to Debut Valeda Light Delivery System at EURETINAhttps://modernod.com/news/lumithera-to-debut-valeda-light-delivery-system-at-euretina/2479887/LumiThera announced that it will debut the Valeda Light Delivery System for the treatment of dry AMD in the exhibition hall at the EURETINA meeting in Vienna. It will also host a symposium on photobiomodulation (PBM) technology entitled, “Photobiomodulation: An Innovative, Mitochondria-targ
- Alcon Introduces New AIR OPTIX Plus HydraGlyde Multifocal Contact Lenseshttps://modernod.com/news/alcon-introduces-new-air-optix-plus-hydraglyde-multifocal-contact-lenses/2479894/Alcon is expanding its multifocal portfolio with the launch of AIR OPTIX plus HydraGlyde multifocal contact lenses. As with Alcon’s other multifocal portfolio contact lens options – including DAILIES TOTAL1, DAILIES AquaComfort Plus, and AIR OPTIX AQUA – this latest innovation offers presbyopic p
- MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-rare-pediatric-disease-designation-by-the-u-s-fda-for-the-treatment-of-achromatopsia/2479906/Gene therapy company MeiraGTx Holdings announced that the FDA has granted rare pediatric disease designation to the company’s gene therapy product candidate AAV-CNGA3 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGA3 gene. ACHM is an inherited r
- Commentary: Endothelial Cell Density After Iris-Fixated Phakic IOLhttps://modernod.com/news/endothelial-cell-density-after-iris-fixated-phakic-iol/2479908/There are three main types of phakic intraocular lenses (pIOL): those secured in the anterior chamber angle, those secured to the iris, and those placed between the crystalline lens and the iris. The latter two types are approved by the US Food and Drug Administration for use in the United States
- UK Calls on Drugmakers to Stockpile 6-Week Supply of Medicines to Cope With “No Deal” Brexithttps://modernod.com/news/uk-calls-on-drugmakers-to-stockpile-6-week-supply-of-medicines-to-cope-with-no-deal-brexit/2479911/The UK’s Department of Health and Social Care has asked pharmaceutical companies that supply drugs to NHS patients to “ensure they have a minimum of six weeks additional supply” of medicines, over and above their usual buffer stocks, in case imports from the EU are disrupted in
- Devices to Expand Role of Surgery in Glaucoma Treatmenthttps://modernod.com/news/devices-to-expand-role-of-surgery-in-glaucoma-treatment/2479914/The glaucoma surgical device market is expected to grow at a rate of nearly 23 percent over the next 5 years, according to a Market Scope report. The market is expected to grow to nearly $1.7 billion by 2023, up from a small base of just under $634 million in 2018. Minimally invasive glauc
- Open-Angle Glaucoma in One Eye Likely to Develop in the Otherhttps://modernod.com/news/open-angle-glaucoma-in-one-eye-likely-to-develop-in-the-other/2479915/Patients with open-angle glaucoma in one eye are at increased risk for developing glaucoma in the second eye, researchers report, according to Reuters Health. “Among patients with newly diagnosed open-angle glaucoma, almost ha
- Lenstec Completes Enrollment of FDA Trial for SBL-3 IOLhttps://modernod.com/news/lenstec-completes-enrollment-of-fda-trial-for-sbl-3-iol/2479919/Lenstec announced that it has completed enrollment of the FDA trial for the SBL-3 IOL. The Lenstec SBL-3 IOL (segmented bifocal lens) is a non-concentric asymmetric multifocal refractive IOL that provides patients with superior near, intermediate, and distance vision. It also improves contrast se
- MeiraGTx Announces AAV-CNGB3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cngb3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2479927/MeiraGTx Holdings announced that the FDA has granted Fast Track designation for its AAV-CNGB3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGB3 gene. ACHM is an inherited retinal disease that severely limits a person’s sight